Yuprev 175 μg Solution for inhalation

    Yuprev 175 μg Solution for inhalation

    S4
    PDF Leaflet Revision Date: 14 February 2023

    API: Revefanacin | Company: Mylan

    Clinical Summary

    Quick overview from the medicine insert

    Indication

    Maintenance treatment of COPD.

    Dosage (summary)

    175 u03bcg once daily via nebuliser.

    Special Populations

    • Elderly
    • Renal impairment

    Pregnancy & Breastfeeding

    Use with caution; not recommended during breastfeeding.

    Key Drug Interactions

    • Anticholinergics
    • OATP1B1 and OATP1B3 inhibitors

    Contraindications

    • Hypersensitivity to revefenacin or excipients

    Common side effects

    • Cough
    • Nasopharyngitis
    • Headache

    Counselling Points

    • Use only with specified nebuliser
    • Discard vial after use
    • Monitor for worsening symptoms

    Serious warnings

    • Paradoxical bronchospasm
    • Worsening of narrow-angle glaucoma
    • Immediate hypersensitivity reactions
    Important Disclaimer

    The Yuprev 175 μg Solution for inhalation professional information leaflet below is the property of Mylan and is provided on Medinsert exactly as issued, with no.. alterations or editorial changes. We make every effort to keep content current by updating documents as soon as new versions become available. Medinsert serves as a trusted access point for healthcare professionals, but does not replace official sources or clinical judgement. For more details, please read our full disclaimer. read more>>

    Healthcare Professionals Only

    This content is for registered healthcare professionals

    Sign in or create a free account to read the full package insert.

    Free for HPCSA-registered professionals. Powered by Medinsert.

    Successfully Stashed! 💊

    This package insert has been safely stored in your digital medical cabinet. No prescription needed to view it later!

    View My Favourites
    WhatsApp Email LinkedIn